Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Becton Dickinson and Co (BDX) vs Bilibili Inc (BILI) Price & Performance

Becton Dickinson and CoTrade
Bilibili IncTrade

Price performance (Past 24H)

Key statistics

Becton Dickinson and Co vs Bilibili Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $49.41B), while Bilibili Inc trades at $17.6 (market cap $7.65B). The key difference: Becton Dickinson and Co is far larger — about 6.5× Bilibili Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.

BDXBILI
Market Cap
$49.41B$7.65B
Sector
HealthMedia
52-Week High
$185.39$35.92
52-Week Low
$138.62$15.96
Enterprise Value
$65.51B$5.49B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Becton Dickinson and Co

BDX trades at $183.71, up 2.27% today, near its consensus price target of $183.00. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $21.84 billion in 2025, with consistent earnings beats in recent quarters, including Q3 2026 EPS of $3.23 beating estimates. The company maintains a dividend of $1.05 per share and recently raised full-year guidance, reflecting operational strength amid tariff pressures.

Outlook remains positive with raised profit guidance and segment growth, but risks include margin pressure from tariffs and a product recall. Analyst sentiment is mixed with 47% buy ratings, suggesting cautious optimism. The stock offers stability as a Dividend Aristocrat with growth catalysts from medical technology advancements, though investors should monitor margin trends and competitive dynamics.

Bilibili Inc

Bilibili (BILI) trades at $17.61, down 7.27% over 24 hours, reflecting bearish technical signals despite strong analyst support. The company reported Q1 2026 EPS of $0.19, beating expectations, with revenue growth projected to $30.8B in 2026. Profit margins improved to 4.58%, though valuation ratios like P/E of 36.24 remain elevated. Recent news highlights a $300 million share repurchase program and upcoming Q2 earnings on August 27, 2026.

The outlook is mixed: bullish fundamentals from earnings beats and buy-side consensus contrast with near-term technical weakness. Key opportunities include user monetization and AI integration, while risks involve competitive pressure and reliance on Chinese market dynamics. The stock's trajectory hinges on Q2 results delivering sustained margin expansion.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX

About Bilibili Inc

Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.

Read more on BILI